The Nature Medicine journal recently published an article entitled, Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.
Points of interest:
- Allogeneic neural progenitors engineered to release glial cell line-derived neurotrophic factor (GDNF) can be safely transplanted into the central nervous system of humans
- Of the 13 participants in the study, GDNF production and graft survival were evident for ≤42 months posttransplantation
- Only 1 person showed an inflammatory reaction or rejection
For more information, click here.
